Raymond M Reilly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7678505/publications.pdf

Version: 2024-02-01

146 papers	5,725 citations	61984 43 h-index	95266 68 g-index
168 all docs	168 docs citations	168 times ranked	6304 citing authors

#	Article	IF	Citations
1	Cellular dosimetry of ¹⁹⁷Hg, ^{197m}Hg and ¹¹¹In: comparison of dose deposition and identification of the cell and nuclear membrane as important targets. International Journal of Radiation Biology, 2023, 99, 53-63.	1.8	4
2	Changing Surface Polyethylene Glycol Architecture Affects Elongated Nanoparticle Penetration into Multicellular Tumor Spheroids. Biomacromolecules, 2022, 23, 3296-3307.	5.4	1
3	Investigating the influence of block copolymer micelle length on cellular uptake and penetration in a multicellular tumor spheroid model. Nanoscale, 2021, 13, 280-291.	5.6	47
4	Site-Specific Conjugation of Metal-Chelating Polymers to Anti-Frizzled-2 Antibodies via Microbial Transglutaminase. Biomacromolecules, 2021, 22, 2491-2504.	5.4	0
5	Dose predictions for [177Lu]Lu-DOTA-panitumumab F(abâ€²)2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(abâ€²)2 â€“ implications for a PET theranostic strategy. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 25.	3.9	5
6	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharmacy and Chemistry, 2021, 6, 31.	3.9	0
7	Imaging of HER2-Positive Tumors in NOD/SCID Mice with Pertuzumab Fab-Hexahistidine Peptide Immunoconjugates Labeled with [99mTc]-(I)-Tricarbonyl Complex. Molecular Imaging and Biology, 2021, 23, 495-504.	2.6	2
8	MR-guided focused ultrasound enhances delivery of trastuzumab to Her2-positive brain metastases. Science Translational Medicine, 2021, 13, eabj4011.	12.4	82
9	Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. Nuclear Medicine and Biology, 2020, 80-81, 37-44.	0.6	7
10	A comparison of DFO and DFO* conjugated to trastuzumab-DM1 for complexing 89Zr â€“ In vitro stability and in vivo microPET/CT imaging studies in NOD/SCID mice with HER2-positive SK-OV-3 human ovarian cancer xenografts. Nuclear Medicine and Biology, 2020, 84-85, 11-19.	0.6	16
11	The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT. International Journal of Pharmaceutics, 2020, 588, 119786.	5.2	4
12	Functionalization of Cellulose Nanocrystals with POEGMA Copolymers via Copper-Catalyzed Azideâ€“Alkyne Cycloaddition for Potential Drug-Delivery Applications. Biomacromolecules, 2020, 21, 2014-2023.	5.4	14
13	Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with ¹⁷⁷Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines. Molecular Pharmaceutics, 2020, 17, 1226-1236.	4.6	14
14	Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(abâ€²)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib. Nuclear Medicine and Biology, 2020, 84-85, 46-54.	0.6	4
15	Synthesis of a metal-chelating polymer with NOTA pendants as a carrier for 64Cu, intended for radioimmunotherapy. European Polymer Journal, 2020, 125, 109501.	5.4	2
16	Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or Î²-particle emitting, 177Lu. EJNMMI Radiopharmacy and Chemistry, 2020, 5, 22.	3.9	10
17	Auger electrons for cancer therapy â€“ a review. EJNMMI Radiopharmacy and Chemistry, 2019, 4, 27.	3.9	196
18	MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with ^{99m}Tc(I) Tricarbonyl Complex. Molecular Pharmaceutics, 2019, 16, 3559-3568.	4.6	10

#	Article	IF	Citations
19	Immuno-PET to Optimize the Dose of Monoclonal Antibodies for Cancer Therapy: How Much Is Enough?. Journal of Nuclear Medicine, 2019, 60, 899-901.	5.0	1
20	Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to ¹⁷⁷Lu. Molecular Pharmaceutics, 2019, 16, 768-778.	4.6	16
21	Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to ¹¹¹In and ¹⁷⁷Luâ€"An EGFR-Targeted Theranostic for Pancreatic Cancer. Molecular Pharmaceutics, 2018, 15, 1150-1159.	4.6	39
22	Tumor uptake and tumor/blood ratios for [89Zr]Zr-DFO-trastuzumab-DM1 on microPET/CT images in NOD/SCID mice with human breast cancer xenografts are directly correlated with HER2 expression and response to trastuzumab-DM1. Nuclear Medicine and Biology, 2018, 67, 43-51.	0.6	10
23	Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with ⁸⁹Zr-Labeled Trastuzumab-DM1: A Comparison with ⁸⁹Zr-Labeled Trastuzumab. Molecular Pharmaceutics, 2018, 15, 3383-3393.	4.6	16
24	CD16⁺NK-92 and anti-CD123 monoclonal antibody prolongs survival in primary human acute myeloid leukemia xenografted mice. Haematologica, 2018, 103, 1720-1729.	3.5	18
25	Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting Î±-particles or Auger electrons. Advanced Drug Delivery Reviews, 2017, 109, 102-118.	13.7	117
26	EGFR-Targeted Metal Chelating Polymers (MCPs) Harboring Multiple Pendant PEG2K Chains for MicroPET/CT Imaging of Patient-Derived Pancreatic Cancer Xenografts. ACS Biomaterials Science and Engineering, 2017, 3, 279-290.	5.2	7
27	64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents. Molecular Pharmaceutics, 2017, 14, 492-501.	4.6	26
28	Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with 177Lu. Pharmaceutical Research, 2017, 34, 579-590.	3.5	61
29	Monte Carlo simulation of radiation transport and dose deposition from locally released gold nanoparticles labeled with¹¹¹In,¹⁷⁷Lu or⁹⁰Y incorporated into tissue implantable depots. Physics in Medicine and Biology, 2017, 62, 8581-8599.	3.0	11
30	Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology. Methods, 2017, 130, 23-35.	3.8	28
31	Development and preclinical studies of ⁶⁴Cu-NOTA-pertuzumab F(abâ€²)₂ for imaging changes in tumor HER2 expression associated with response to trastuzumab by PET/CT. MAbs, 2017, 9, 154-164.	5.2	39
32	Monte Carlo N-Particle (MCNP) Modeling of the Cellular Dosimetry of⁶⁴Cu: Comparison with MIRDcell S Values and Implications for Studies of Its Cytotoxic Effects. Journal of Nuclear Medicine, 2017, 58, 339-345.	5.0	29
33	Dual-Receptorâ€"Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using ¹⁷⁷Lu- or ¹¹¹In-Labeled Bispecific Radioimmunoconjugates. Journal of Nuclear Medicine, 2016, 57, 444-452.	5.0	38
34	Paradoxical effects of Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates on hCD45 + cells in the bone marrow and spleen of leukemia-engrafted NOD/SCID or NRG mice. Nuclear Medicine and Biology, 2016, 43, 635-641.	0.6	8
35	111In-labeled trastuzumab-modified gold nanoparticles are cytotoxic in vitro to HER2-positive breast cancer cells and arrest tumor growth in vivo in athymic mice after intratumoral injection. Nuclear Medicine and Biology, 2016, 43, 818-826.	0.6	63
36	Depot system for controlled release of gold nanoparticles with precise intratumoral placement by permanent brachytherapy seed implantation (PSI) techniques. International Journal of Pharmaceutics, 2016, 515, 729-739.	5.2	16

#	Article	IF	Citations
37	Intratumorally Injected ¹⁷⁷Lu-Labeled Gold Nanoparticles: Gold Nanoseed Brachytherapy with Application for Neoadjuvant Treatment of Locally Advanced Breast Cancer. Journal of Nuclear Medicine, 2016, 57, 936-942.	5.0	92
38	Stability and Biodistribution of Thiol-Functionalized and ¹⁷⁷Lu-Labeled Metal Chelating Polymers Bound to Gold Nanoparticles. Biomacromolecules, 2016, 17, 1292-1302.	5.4	32
39	Auger electron-emitting 111 In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123 + /CD131 â˜ phenotype of leukemia stem cells. Applied Radiation and Isotopes, 2016, 110, 1-7.	1.5	13
40	A radiolabeled antibody targeting CD123+ leukemia stem cells â€“ initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Research Reports, 2015, 4, 55-59.	0.4	15
41	Trastuzumab Labeled to High Specific Activity with ¹¹¹In by Site-Specific Conjugation to a Metal-Chelating Polymer Exhibits Amplified Auger Electron-Mediated Cytotoxicity on HER2-Positive Breast Cancer Cells. Molecular Pharmaceutics, 2015, 12, 1951-1960.	4.6	26
42	Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab. Nuclear Medicine and Biology, 2015, 42, 78-84.	0.6	14
43	MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using 64Cu-NOTA-panitumumab F(ab')2 fragments. Nuclear Medicine and Biology, 2015, 42, 71-77.	0.6	35
44	Advancing Novel Molecular Imaging Agents from Preclinical Studies to First-in-Humans Phase I Clinical Trials in Academiaâ€"A Roadmap for Overcoming Perceived Barriers. Bioconjugate Chemistry, 2015, 26, 625-632.	3.6	12
45	Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the Î²-Particle-Emitter, ¹⁷⁷Lu. Molecular Pharmaceutics, 2015, 12, 3963-3972.	4.6	67
46	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111 In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice. Nuclear Medicine and Biology, 2015, 42, 931-938.	0.6	14
47	Metal-Chelating Polymers (MCPs) with Zwitterionic Pendant Groups Complexed to Trastuzumab Exhibit Decreased Liver Accumulation Compared to Polyanionic MCP Immunoconjugates. Biomacromolecules, 2015, 16, 3613-3623.	5.4	28
48	Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies. Journal of Controlled Release, 2015, 219, 295-312.	9.9	11
49	Kit for the preparation of 111In-labeled pertuzumab injection for imaging response of HER2-positive breast cancer to trastuzumab (Herceptin). Applied Radiation and Isotopes, 2015, 95, 135-142.	1.5	13
50	MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131â˜ epitope expressed by leukemia stem cells. Leukemia Research, 2014, 38, 1367-1373.	0.8	16
51	Synthesis of Polyglutamide-Based Metal-Chelating Polymers and Their Site-Specific Conjugation to Trastuzumab for Auger Electron Radioimmunotherapy. Biomacromolecules, 2014, 15, 2027-2037.	5.4	34
52	The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 111In-NLS-7G3 radioimmunoconjugates. Nuclear Medicine and Biology, 2014, 41, 377-383.	0.6	30
53	Intracellular Routing in Breast Cancer Cells of Streptavidin-Conjugated Trastuzumab Fab Fragments Linked to Biotinylated Doxorubicin-Functionalized Metal Chelating Polymers. Biomacromolecules, 2014, 15, 715-725.	5.4	19
54	Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 181-92.	1.0	27

#	Article	IF	Citations
55	Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells. Pharmaceutical Research, 2013, 30, 1999-2009.	3.5	24
56	Investigation of the effects of cell model and subcellular location of gold nanoparticles on nuclear dose enhancement factors using Monte Carlo simulation. Medical Physics, 2013, 40, 114101.	3.0	32
57	MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using 111In-labeled bispecific radioimmunoconjugates. Breast Cancer Research and Treatment, 2013, 138, 709-718.	2.5	20
58	Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments. Nuclear Medicine and Biology, 2013, 40, 630-637.	0.6	22
59	Active Targeting of Block Copolymer Micelles with Trastuzumab Fab Fragments and Nuclear Localization Signal Leads to Increased Tumor Uptake and Nuclear Localization in HER2-Overexpressing Xenografts. Molecular Pharmaceutics, 2013, 10, 4229-4241.	4.6	45
60	Molecularly targeted gold nanoparticles enhance the radiation response of breast cancer cells and tumor xenografts to X-radiation. Breast Cancer Research and Treatment, 2013, 137, 81-91.	2.5	135
61	The Effect of Metal-Chelating Polymers (MCPs) for 111In Complexed via the Streptavidin-Biotin System to Trastuzumab Fab Fragments on Tumor and Normal Tissue Distribution in Mice. Pharmaceutical Research, 2013, 30, 104-116.	3.5	16
62	Positron-Emission Tomography Imaging of the TSPO with [¹⁸F]FEPPA in a Preclinical Breast Cancer Model. Cancer Biotherapy and Radiopharmaceuticals, 2013, 28, 254-259.	1.0	17
63	Estrone-3-Sulphate, a Potential Novel Ligand for Targeting Breast Cancers. PLoS ONE, 2013, 8, e64069.	2.5	15
64	Development of an Epidermal Growth Factor Derivative with EGFR Blocking Activity. PLoS ONE, 2013, 8, e69325.	2.5	18
65	Small-Animal SPECT/CT of HER2 and HER3 Expression in Tumor Xenografts in Athymic Mice Using Trastuzumab Fabâ€“Heregulin Bispecific Radioimmunoconjugates. Journal of Nuclear Medicine, 2012, 53, 1943-1950.	5.0	29
66	Feasibility Evaluation of Radioimmunoguided Surgery of Breast Cancer. International Journal of Molecular Imaging, 2012, 2012, 1-10.	1.3	1
67	111In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer. Breast Cancer Research and Treatment, 2012, 135, 189-200.	2.5	47
68	Block Copolymer Micelles Target Auger Electron Radiotherapy to the Nucleus of HER2-Positive Breast Cancer Cells. Biomacromolecules, 2012, 13, 455-465.	5.4	53
69	Biotinylated Polyacrylamide-Based Metal-Chelating Polymers and Their Influence on Antigen Recognition Following Conjugation to a Trastuzumab Fab Fragment. Biomacromolecules, 2012, 13, 2831-2842.	5.4	15
70	Effect of Pendant Group Structure on the Hydrolytic Stability of Polyaspartamide Polymers under Physiological Conditions. Biomacromolecules, 2012, 13, 1296-1306.	5.4	25
71	Role of Antibody-Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in Vivo. Molecular Pharmaceutics, 2012, 9, 2168-2179.	4.6	90
72	Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles. Journal of Controlled Release, 2012, 157, 366-374.	9.9	36

#	Article	IF	Citations
73	Irradiated NK-92 Targets AML Leukemic Stem Cells in Vivo and Gene-Modified CD16+NK-92 Mediates Antibody Dependent Cell Mediated Cytotoxicity (ADCC) Against CD123+ Cells. Blood, 2012, 120, 1909-1909.	1.4	0
74	A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Nuclear Medicine and Biology, 2011, 38, 129-136.	0.6	19
75	Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nuclear Medicine and Biology, 2011, 38, 953-959.	0.6	15
76	A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Research, 2011, 1, 15.	2.5	33
77	Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: Comparison with manual counting. International Journal of Radiation Biology, 2011, 87, 1135-1146.	1.8	97
78	ErbB-2 Blockade and Prenyltransferase Inhibition Alter Epidermal Growth Factor and Epidermal Growth Factor Receptor Trafficking and Enhance ¹¹¹In-DTPA-hEGF Auger Electron Radiation Therapy. Journal of Nuclear Medicine, 2011, 52, 776-783.	5.0	16
79	Auger Electron Radioimmunotherapeutic Agent Specific for the CD123⁺/CD131^{â^'} Phenotype of the Leukemia Stem Cell Population. Journal of Nuclear Medicine, 2011, 52, 1465-1473.	5.0	40
80	In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels. Pharmaceutical Research, 2010, 27, 2343-2355.	3.5	123
81	Methotrexate, Paclitaxel, and Doxorubicin Radiosensitize HER2-Amplified Human Breast Cancer Cells to the Auger Electronâ€"Emitting Radiotherapeutic Agent ¹¹¹In-NLS-Trastuzumab. Journal of Nuclear Medicine, 2010, 51, 477-483.	5.0	49
82	Cellular Dosimetry of ¹¹¹In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity. Journal of Nuclear Medicine, 2010, 51, 462-470.	5.0	59
83	Antiproliferative Effects of 111In- or 177Lu-DOTATOC on Cells Exposed to Low Multiplicity-of-Infection Double-Deleted Vaccinia Virus Encoding Somatostatin Subtype-2 Receptor. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 325-333.	1.0	10
84	Antitumor Effects and Normal-Tissue Toxicity of ¹¹¹In-Nuclear Localization Sequence-Trastuzumab in Athymic Mice Bearing HER-Positive Human Breast Cancer Xenografts. Journal of Nuclear Medicine, 2010, 51, 1084-1091.	5.0	61
85	Multifunctional Block Copolymer Micelles for the Delivery of ¹¹¹In to EGFR-Positive Breast Cancer Cells for Targeted Auger Electron Radiotherapy. Molecular Pharmaceutics, 2010, 7, 177-186.	4.6	30
86	The Effects of Particle Size and Molecular Targeting on the Intratumoral and Subcellular Distribution of Polymeric Nanoparticles. Molecular Pharmaceutics, 2010, 7, 1195-1208.	4.6	302
87	111In- or 99mTc-labeled recombinant VEGF bioconjugates: in vitro evaluation of their cytotoxicity on porcine aortic endothelial cells overexpressing Flt-1 receptors. Nuclear Medicine and Biology, 2010, 37, 105-115.	0.6	18
88	Design and Characterization of HER-2-Targeted Gold Nanoparticles for Enhanced X-radiation Treatment of Locally Advanced Breast Cancer. Molecular Pharmaceutics, 2010, 7, 2194-2206.	4.6	107
89	MicroSPECT/CT Imaging of Human Leukemia Engraftment In NOD-Scid Mice Using [111In]-Labeled 7G3 Anti-CD123 Antibodies. Blood, 2010, 116, 968-968.	1.4	0
90	Micro-SPECT/CT with ¹¹¹In-DTPA-Pertuzumab Sensitively Detects Trastuzumab-Mediated HER2 Downregulation and Tumor Response in Athymic Mice Bearing MDA-MB-361 Human Breast Cancer Xenografts. Journal of Nuclear Medicine, 2009, 50, 1340-1348.	5.0	76

#	Article	IF	Citations
91	¹⁸F-FDG Small-Animal PET/CT Differentiates Trastuzumab-Responsive from Unresponsive Human Breast Cancer Xenografts in Athymic Mice. Journal of Nuclear Medicine, 2009, 50, 1848-1856.	5.0	36
92	¹¹¹In-Labeled Immunoconjugates (ICs) Bispecific for the Epidermal Growth Factor Receptor (EGFR) and Cyclin-Dependent Kinase Inhibitor, p27^{Kip1}. Cancer Biotherapy and Radiopharmaceuticals, 2009, 24, 163-173.	1.0	13
93	Aiming for a Direct Hit: Combining Molecular Imaging with Targeted Cancer Therapy. Journal of Nuclear Medicine, 2009, 50, 1017-1019.	5.0	3
94	Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 81-93.	6.4	108
95	In vivo monitoring of intranuclear p27kip1 protein expression in breast cancer cells during trastuzumab (Herceptin) therapy. Nuclear Medicine and Biology, 2009, 36, 811-819.	0.6	9
96	Computational analysis of the number, area and density of Î³-H2AX foci in breast cancer cells exposed to¹¹¹In-DTPA-hEGF or Î³-rays using Image-J software. International Journal of Radiation Biology, 2009, 85, 262-271.	1.8	74
97	Noninvasive Monitoring of the Fate of ¹¹¹In-Labeled Block Copolymer Micelles by High Resolution and High Sensitivity MicroSPECT/CT Imaging. Molecular Pharmaceutics, 2009, 6, 581-592.	4.6	78
98	Synthesis and preliminary biological evaluations of [18F]-1-deoxy-1-fluoro-scyllo-inositol. Chemical Communications, 2009, , 5527.	4.1	17
99	Properties of [111In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection. Nuclear Medicine and Biology, 2008, 35, 101-110.	0.6	18
100	The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of 111In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin). Nuclear Medicine and Biology, 2008, 35, 645-653.	0.6	36
101	Update:Peptide Motifs for Insertion of Radiolabeled Biomolecules into Cells and Routing to the Nucleus for Cancer Imaging or Radiotherapeutic Applications. Cancer Biotherapy and Radiopharmaceuticals, 2008, 23, 3-24.	1.0	55
102	Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electronâ€“Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate. Journal of Nuclear Medicine, 2008, 49, 1498-1505.	5.0	73
103	Drug-Resistant AML Cells and Primary AML Specimens Are Killed by ¹¹¹In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences. Journal of Nuclear Medicine, 2008, 49, 1546-1554.	5.0	50
104	Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to ¹¹¹In-DTPA-hEGF. Journal of Nuclear Medicine, 2008, 49, 1353-1361.	5.0	57
105	Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor. Journal of Nuclear Medicine, 2007, 48, 1562-1570.	5.0	35
106	111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer. Journal of Nuclear Medicine, 2007, 48, 1357-1368.	5.0	163
107	Carbon Nanotubes: Potential Benefits and Risks of Nanotechnology in Nuclear Medicine. Journal of Nuclear Medicine, 2007, 48, 1039-1042.	5.0	103
108	Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nuclear Medicine and Biology, 2007, 34, 37-46.	0.6	42

#	Article	IF	Citations
109	Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF. Nuclear Medicine and Biology, 2007, 34, 887-896.	0.6	41
110	Apoptotic Epidermal Growth Factor (EGF)-Conjugated Block Copolymer Micelles as a Nanotechnology Platform for Targeted Combination Therapy. Molecular Pharmaceutics, 2007, 4, 769-781.	4.6	57
111	Construction and Evaluation of the Tumor Imaging Properties of123I-Labeled Recombinant and Enzymatically Generated Fab Fragments of the TAG-72 Monoclonal Antibody CC49. Bioconjugate Chemistry, 2007, 18, 677-684.	3.6	9
112	123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21WAF-1/Cip-1. European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 368-377.	6.4	46
113	HIV-1 Tat Peptide Immunoconjugates Differentially Sensitize Breast Cancer Cells to Selected Antiproliferative Agents That Induce the Cyclin-Dependent Kinase Inhibitor p21WAF-1/CIP-1. Bioconjugate Chemistry, 2006, 17, 1280-1287.	3.6	19
114	Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 301-310.	6.4	37
115	Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties. Cancer Chemotherapy and Pharmacology, 2006, 59, 61-69.	2.3	23
116	In vitro andin vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques. International Journal of Cancer, 2006, 119, 414-422.	5.1	67
117	Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens. Journal of Nuclear Medicine, 2006, 47, 196-9.	5.0	17
118	Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. Journal of Nuclear Medicine, 2006, 47, 827-36.	5.0	69
119	Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. Journal of Nuclear Medicine, 2006, 47, 1023-31.	5.0	51
120	Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [99mTc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine Communications, 2005, 26, 427-432.	1.1	64
121	Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments. Nuclear Medicine and Biology, 2005, 32, 51-58.	0.6	133
122	Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. Journal of Nuclear Medicine, 2005, 46, 1537-45.	5.0	49
123	A human transferrin-vascular endothelial growth factor (hnTf-VEGF) fusion protein containing an integrated binding site for (111)In for imaging tumor angiogenesis. Journal of Nuclear Medicine, 2005, 46, 1745-52.	5.0	41
124	The Immunoreactivity of Radiolabeled Antibodiesâ€"Its Impact on Tumor Targeting and Strategies for Preservation. Cancer Biotherapy and Radiopharmaceuticals, 2004, 19, 669-672.	1.0	11
125	Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using 111In-Pentetreotide. Molecular Therapy, 2004, 10, 553-561.	8.2	72
126	Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage. Nuclear Medicine Communications, 2004, 25, 1125-1130.	1.1	9

#	Article	IF	Citations
127	A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications. Journal of Nuclear Medicine, 2004, 45, 701-8.	5.0	24
128	Antisense imaging of epidermal growth factor-induced p21 WAF-1/CIP-1 gene expression in MDA-MB-468 human breast cancer xenografts. European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30, 1273-1280.	6.4	14
129	Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. Journal of Nuclear Medicine, 2003, 44, 1469-78.	5.0	53
130	Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation. Cancer Research, 2003, 63, 5950-6.	0.9	175
131	Fusion of the CH1 Domain of IgG1to Epidermal Growth Factor (EGF) Prolongs its Retention in the Blood but Does Not Increase Tumor Uptake. Cancer Biotherapy and Radiopharmaceuticals, 2002, 17, 665-671.	1.0	3
132	Comparative antiproliferative effects of 111In-DTPA-hEGF, chemotherapeutic agents and Î³-radiation on EGFR-positive breast cancer cells. Nuclear Medicine and Biology, 2002, 29, 693-699.	0.6	30
133	Amplified delivery of indium-111 to EGFR-positive human breast cancer cells. Nuclear Medicine and Biology, 2001, 28, 895-902.	0.6	19
134	Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In. Nuclear Medicine Communications, 2001, 22, 587-595.	1.1	9
135	Oral Delivery of Antibodies. Clinical Pharmacokinetics, 1997, 32, 313-323.	3.5	107
136	Pre-operative assessment of axillary lymph node status in patients with breast adenocarcinoma using intravenous 99mtechnetium mAb-170H.82 (Tru-ScintÂ®ADâ„¢). Breast Cancer Research and Treatment, 1997, 45, 29-37.	2.5	18
137	Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and 111In-DTPA-biocytin. Nuclear Medicine and Biology, 1996, 23, 459-466.	0.6	24
138	A New Radioligand for the Epidermal Growth Factor Receptor:â€‰ 111In Labeled Human Epidermal Growth Factor Derivatized with a Bifunctional Metal-Chelating Peptide. Bioconjugate Chemistry, 1996, 7, 721-721.	3.6	0
139	A New Radioligand for the Epidermal Growth Factor Receptor: 111In-Labeled Human Epidermal Growth Factor Derivatized with a Bifunctional Metal-Chelating Peptide. Bioconjugate Chemistry, 1995, 6, 683-690.	3.6	21
140	In vitro and in vivo evaluation of streptavidin immunoconjugates of the second generation TAG-72 monoclonal antibody CC49. Nuclear Medicine and Biology, 1995, 22, 77-86.	0.6	20
141	Problems of Delivery of Monoclonal Antibodies. Clinical Pharmacokinetics, 1995, 28, 126-142.	3.5	151
142	Compartmental analysis of the pharmacokinetics of radioiodinated monoclonal antibody B72.3 in colon cancer patients. Nuclear Medicine and Biology, 1993, 20, 57-64.	0.6	3
143	Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecologic Oncology, 1992, 47, 102-109.	1.4	46
144	Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. International Journal of Immunopharmacology, 1983, 5, 307-314.	1.1	15

#	Article	IF	Citations
145	The Radiopharmaceutical Science of Monoclonal Antibodies and Peptides for Imaging and Targetedin situ Radiotherapy of Malignancies. , 0, , 883-942.		2
146	Biopharmaceuticals as Targeting Vehicles forIn situ Radiotherapy of Malignancies. , 0, , 497-535.		17